Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624595 | 0.91 | MAPT (0.57) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL6716570 | 0.91 | MAPT (0.57) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL4433804 | 0.84 | SIRT6 (0.71) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL4067852 | 0.83 | MAPT (0.56) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL25176334 | 0.83 | MAPT (0.64) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL223626 | 0.83 | MAPT (1.00) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL85552 | 0.83 | MAPT (1.00) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL6607374 | 0.83 | MAPT (1.00) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL3486900 | 0.82 | MAPT (0.58) | MAPTALDH1A1SIRT6POLBADRB1 | |
| SCHEMBL25197695 | 0.81 | POLB (0.67) | MAPTALDH1A1SIRT6POLBADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | MAPT 1277/4885ALDH1A1 4230/4885SIRT6 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.